Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) Gains from Investment Securities (2018 - 2019)

DiaMedica Therapeutics (DMAC) has 2 years of Gains from Investment Securities data on record, last reported at $71000.0 in Q4 2019.

  • For Q4 2019, Gains from Investment Securities rose 9.23% year-over-year to $71000.0; the TTM value through Dec 2019 reached $75000.0, down 27.88%, while the annual FY2022 figure was $6000.0, 95.45% down from the prior year.
  • Gains from Investment Securities reached $71000.0 in Q4 2019 per DMAC's latest filing, up from $1000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $71000.0 in Q4 2019 and bottomed at $1000.0 in Q2 2019.